BIO-TECHNE Corp Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term (Deprecated 2012-01-31)
BIO-TECHNE Corp (TECH) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term (Deprecated 2012-01-31) of 6 Year for the 9-month period ending 2012-03-31, per its 10-Q filed 2012-05-10.
Discontinued › Notes › Compensation Related Costs
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm · last filed 2012-05-10
- BIO-TECHNE Corp share-based compensation arrangement by share-based payment award, options, exercisable, weighted average remaining contractual term (deprecated 2012-01-31) for the quarter ending 2011-09-30 was 5.80 Year.
- BIO-TECHNE Corp share-based compensation arrangement by share-based payment award, options, exercisable, weighted average remaining contractual term (deprecated 2012-01-31) for fiscal 2011 was 6.00 Year.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term (Deprecated 2012-01-31) 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term (Deprecated 2012-01-31) 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term (Deprecated 2012-01-31) 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term (Deprecated 2012-01-31) 12 month |
|---|---|---|---|---|
| 2012-03-31 | 6.00 Year 10-Q · filed 2012-05-10 | |||
| 2011-12-31 | 6.10 Year 10-Q · filed 2012-02-07 | |||
| 2011-09-30 | 5.80 Year 10-Q · filed 2011-11-09 | |||
| 2011-06-30 | 6.00 Year 10-K · filed 2011-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |